Granite Point Capital Management, L.P. Stoke Therapeutics, Inc. Transaction History

Granite Point Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 12, 2020	SELL	$16.8 - $34.15 $221,760 - $450,780	-13,200 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$20.01 - $30.79 $76,038 - $117,002	-3,800 Reduced 22.35%	13,200 $374,000
Q3 2019 Oct 30, 2019	SELL	$20.53 - $37.72 $349,010 - $641,240	-17,000 Reduced 50.0%	17,000 $365,000
Q2 2019 Jul 29, 2019	BUY	$25.53 - $29.17 $868,020 - $991,780	34,000 New	34,000 $992,000

125

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $367M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.